bioAffinity Technologies Q3 net loss widens to $5.28 million; revenue falls 26% to $1.07 million
BIAF•bioAffinity Technologies’ third-quarter 2026 net loss widened to $5.28 million, while revenue fell 26% year over year to $1.07 million. Operating expenses rose 23% to $4.58 million.
1. Quarterly results
bioAffinity Technologies reported a third-quarter 2026 net loss of $5.28 million. Revenue declined 26% year over year to $1.07 million, primarily due to lower CyPath Lung reimbursement and fewer laboratory cases, while operating expenses rose 23% to $4.58 million.
2. CyPath and collaboration
CyPath Lung testing revenue climbed 79% year over year to approximately $1.1 million in the first nine months of 2026. A collaboration with Pictor will support development and potential commercialization of diagnostic tests for lung inflammation in asthma and COPD patients.
